THAT WHICH IS CLAIMED:

1. A compound of the formula:



wherein Q is $(CH_2)_u$, Q^i is $(CH_2)_v$, Q^{ii} is $(CH_2)_w$, Q^{iii} is $(CH_2)_x$, and Q^{iv} is $(CH_2)_y$ where u, v, w and x are individually 0, 1, 2, 3 or 4 and y is 1 or 2; Z is a non-hydrogen substituent species characterized as having a sigma m value between -0.3 and about 0.75; j is from 0 to 10; R is hydrogen or lower alkyl; and Cy is



where each of X, X' and X" are individually nitrogen, nitrogen bonded to oxygen or carbon bonded to a substituent species characterized as having a sigma m value between about –0.3 and about 0.75; A is O or C=O; D is a non-hydrogen substituent species characterized as having a sigma m value between about –0.3 and about 0.75; k is 0, 1 or 2; and Cx is selected from a group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, non-aromatic heterocyclylalkyl and substituted non-aromatic heterocyclylalkyl.

2. The compound of Claim 1, wherein X" is nitrogen.

3. The compound of Claim 1, wherein X' and X" are nitrogen.

4. The compound of Claim 1, wherein j is 0, 1 or 2.

5. The compound of Claim 1, wherein the values of u, v, w, x and y are selected to provide a 7-, 8- or 9-membered diazabicyclic ring.

6. The compound of Claim 1, wherein Cx is selected from the group consisting of:



wherein Y, Y', Y" and Y'" are individually nitrogen, nitrogen bonded to oxygen, or carbon bonded to hydrogen or a substituent species, G; E is oxygen, sulfur or nitrogen bonded to hydrogen or a substituent species, G; E', E" and E'" are individually nitrogen or carbon bonded to hydrogen or a substituent species, G; m is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; and G is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, -F, -Cl, -Br, -I, -OR', -NR'R", $-CF_3$, -CN, $-N_3$, $-NO_2$, $-C_2R'$, -SR', -SOR', $-SO_2CH_3$, $-SO_2NR'R"$, -C(=O)NR'R", -NR'C(=O)R", $-NR'SO_2R"$, -C(=O)R', -C(=O)OR', $-(CH_2)_qOR'$, -OC(=O)R', $-(CR'R")_qOCH_2C_2R'$, $-(CR'R")_qC(=O)R'$, $-O(CR'R")_qC(=O)R'$, $-C_2(CR'R")_qO\ R'$, $-(CR'R")_qNR'R"$, -OC(=O)NR'R" and

–NR'C(=O)OR' where R' and R" are individually hydrogen, lower alkyl, an aromatic group-containing species or a substituted aromatic group-containing species, and q is an integer from 1 to 6.

7. The compound of Claim 6, wherein Y, Y', Y" and Y"' all are carbon bonded to a substituent species.

8. The compound of Claim 6, wherein one or two of Y, Y', Y" and Y"' are nitrogen and the remaining are carbon bonded to a substituent species.

9. The compound of Claim 6, wherein E', E" and E"' all are carbon bonded to substituent species.

10. The compound of Claim 6, wherein one or two of E', E" and E"' are nitrogen and the remaining are carbon bonded to substituent species.

11. The compound of Claim 1, selected from the group consisting of (1S,4S)-2-(5-(3-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(4-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(4-fluorophenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(3-thienyl)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane and (1S,4S)-2-(5-benzoyl-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane.

12. A compound of the formula:



wherein Q is $(CH_2)_u$, Q^i is $(CH_2)_v$, Q^{ii} is $(CH_2)_w$, Q^{iii} is $(CH_2)_x$, and Q^{iv} is $(CH_2)_y$ where u, v, w and x are individually 0, 1, 2, 3 or 4 and y is 1 or 2; ; Z is a non-hydrogen substituent species characterized as having a sigma m value between -0.3 and about 0.75; j is from 0 to 10; R is hydrogen or lower alkyl; and Cy is



where each of X, X' and X" are individually nitrogen, nitrogen bonded to oxygen or carbon bonded to a substituent species characterized as having a sigma m value between about –0.3 and about 0.75; A is a covalent bond; D is a non-hydrogen substituent species characterized as having a sigma m value between about –0.3 and about 0.75; k is 0, 1 or 2; and Cx is selected from a group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, non-aromatic heterocyclylalkyl and substituted non-aromatic heterocyclylalkyl, with the proviso that the diazabicyclic ring is not 2,5-diazabicyclo[2.2.1]heptane and/or Cx is not phenyl or substituted phenyl.

13. The compound of Claim 12, wherein X" is nitrogen.

14. The compound of Claim 12, wherein X' and X" are nitrogen.

15. The compound of Claim 12, wherein j is 0, 1 or 2.

16. The compound of Claim 12, wherein the values of u, v, w, x and y are selected to provide a 7-, 8- or 9-membered diazabicyclic ring.

17. The compound of Claim 12, wherein Cx is selected from the group consisting of:



wherein Y, Y', Y" and Y"' are individually nitrogen, nitrogen bonded to oxygen, or carbon bonded to hydrogen or a substituent species, G; E is oxygen, sulfur or nitrogen bonded to hydrogen or a substituent species, G; E', E" and E"' are individually nitrogen or carbon bonded to hydrogen or a substituent species, G; m is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; and G is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, -F, -Cl, -Br, -I, -OR', -NR'R", $-CF_3$, -CN, $-N_3$, $-NO_2$, $-C_2R'$, -SR', -SOR', $-SO_2CH_3$, $-SO_2NR'R"$, -C(=O)NR'R", -NR'C(=O)R", $-NR'SO_2R"$, -C(=O)R', -C(=O)OR', $-(CH_2)_qOR'$, -OC(=O)R', $-(CR'R")_qOCH_2C_2R'$, $-(CR'R")_qC(=O)R'$, $-O(CR'R")_qC(=O)R'$, $-C_2(CR'R")_qO\ R'$, $-(CR'R")_qNR'R"$, -OC(=O)NR'R" and

–NR'C(=O)OR' where R' and R" are individually hydrogen, lower alkyl, an aromatic group-containing species or a substituted aromatic group-containing species, and q is an integer from 1 to 6.

18. The compound of Claim 17, wherein Y, Y', Y" and Y"' all are carbon bonded to a substituent species.

19. The compound of Claim 17, wherein one or two of Y, Y', Y" and Y"' are nitrogen and the remaining are carbon bonded to a substituent species.

20. The compound of Claim 17, wherein E', E" and E"' all are carbon bonded to substituent species.

21. The compound of Claim 17, wherein one or two of E', E" and E"' are nitrogen and the remaining are carbon bonded to substituent species.

22. A pharmaceutical composition useful for treatment of central nervous system disorders comprising a therapeutically effective amount of a compound of the formula:



wherein Q is $(CH_2)_u$, Q^i is $(CH_2)_v$, Q^{ii} is $(CH_2)_w$, Q^{iii} is $(CH_2)_x$, and Q^{iv} is $(CH_2)_y$ where u, v, w and x are individually 0, 1, 2, 3 or 4 and y is 1 or 2; Z is a non-hydrogen substituent species characterized as having a sigma m value between -0.3 and about 0.75; j is from 0 to 10; R is hydrogen or lower alkyl; and Cy is



where each of X, X' and X" are individually nitrogen, nitrogen bonded to oxygen or carbon bonded to a substituent species characterized as having a sigma m value between about –0.3 and about 0.75; A is O or C=O; D is a non-hydrogen substituent species characterized as having a sigma m value between about –0.3 and about 0.75; k is 0, 1 or 2; and Cx is selected from a group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, non-aromatic heterocyclylalkyl and substituted non-aromatic heterocyclylalkyl.

23. The pharmaceutical composition of Claim 22, wherein X" is nitrogen.

24. The pharmaceutical composition of Claim 22, wherein X' and X" are nitrogen.

25. The pharmaceutical composition of Claim 22, wherein j, is 0, 1 or 2.

26. The pharmaceutical composition of Claim 22, wherein the values of u, v, w, x and y are selected to provide a 7-, 8- or 9-membered diazabicyclic ring.

27. The pharmaceutical composition of Claim 22, wherein Cx is selected from the group consisting of:



wherein Y, Y', Y" and Y"' are individually nitrogen, nitrogen bonded to oxygen, or carbon bonded to hydrogen or a substituent species, G; E is oxygen, sulfur or nitrogen bonded to hydrogen or a substituent species, G; E', E" and E"' are individually nitrogen or carbon bonded to hydrogen or a substituent species, G; m is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; and G is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, -F, -Cl, -Br, -I, -OR', -NR'R", $-CF_3$, -CN, $-N_3$, $-NO_2$, $-C_2R'$, -SR', -SOR', $-SO_2CH_3$, $-SO_2NR'R"$, -C(=O)NR'R", -NR'C(=O)R", $-NR'SO_2R"$, -C(=O)R', -C(=O)OR', $-(CH_2)_qOR'$, -OC(=O)R', $-(CR'R")_qOCH_2C_2R'$, $-(CR'R")_qC(=O)R'$, $-O(CR'R")_qC(=O)R'$, $-C_2(CR'R")_qO$ R', $-(CR'R")_qNR'R"$, -OC(=O)NR'R" and –NR'C(=O)OR' where R' and R" are individually hydrogen, lower alkyl, an aromatic group-containing species or a substituted aromatic group-containing species, and q is an integer from 1 to 6.

28. The pharmaceutical composition of Claim 27, wherein Y, Y', Y" and Y"' all are carbon bonded to a substituent species.

29. The pharmaceutical composition of Claim 27, wherein one or two of Y, Y', Y" and Y"' are nitrogen and the remaining are carbon bonded to a substituent species.

30. The pharmaceutical composition of Claim 27, wherein E', E" and E'" all are carbon bonded to substituent species.

31. The pharmaceutical composition of Claim 27, wherein one or two of E', E" and E'" are nitrogen and the remaining are carbon bonded to substituent species.

32. The pharmaceutical composition of Claim 27, wherein the compound is selected from the group consisting of (1S,4S)-2-(5-(3-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(4-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(4-fluorophenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(3-thienyl)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane and (1S,4S)-2-(5-benzoyl-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane.

33. A pharmaceutical composition useful for treatment of central nervous system disorders comprising a therapeutically effective amount of a compound of the formula:



wherein Q is $(CH_2)_u$, Q^i is $(CH_2)_v$, Q^{ii} is $(CH_2)_w$, Q^{iii} is $(CH_2)_x$, and Q^{iv} is $(CH_2)_y$ where u, v, w and x are individually 0, 1, 2, 3 or 4 and y is 1 or 2; ; Z is a non-hydrogen substituent species characterized as having a sigma m value between -0.3 and about 0.75; j is from 0 to 10; R is hydrogen or lower alkyl; and Cy is



where each of X, X' and X" are individually nitrogen, nitrogen bonded to oxygen or carbon bonded to a substituent species characterized as having a sigma m value between about –0.3 and about 0.75; A is a covalent bond; D is a non-hydrogen substituent species characterized as having a sigma m value between about –0.3 and about 0.75; k is 0, 1 or 2; and Cx is selected from a group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, non-aromatic heterocyclylalkyl and substituted non-aromatic heterocyclylalkyl, with the proviso that the diazabicyclic ring is not 2,5-diazabicyclo[2.2.1]heptane and/or Cx is not phenyl or substituted phenyl.

34. The pharmaceutical composition of Claim 33, wherein X" is nitrogen.

35. The pharmaceutical composition of Claim 33, wherein X' and X" are nitrogen.

36. The pharmaceutical composition of Claim 33, wherein j is 0, 1 or 2.

37. The pharmaceutical composition of Claim 33, wherein the values of u, v, w, x and y are selected to provide a 7-, 8- or 9-membered diazabicyclic ring.

38. The pharmaceutical composition of Claim 33, wherein Cx is selected from the group consisting of:



wherein Y, Y', Y" and Y"' are individually nitrogen, nitrogen bonded to oxygen, or carbon bonded to hydrogen or a substituent species, G; E is oxygen, sulfur or nitrogen bonded to hydrogen or a substituent species, G; E', E" and E"' are individually nitrogen or carbon bonded to hydrogen or a substituent species, G; m is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; and G is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, -F, -Cl, -Br, -I, -OR', -NR'R", $-CF_3$, -CN, $-N_3$, $-NO_2$, $-C_2R'$, -SR', -SOR', $-SO_2CH_3$, $-SO_2NR'R"$, -C(=O)NR'R", -NR'C(=O)R", $-NR'SO_2R"$, -C(=O)R', -C(=O)OR', $-(CH_2)_qOR'$, -OC(=O)R', $-(CR'R")_qOCH_2C_2R'$, $-(CR'R")_qC(=O)R'$, $-O(CR'R")_qC(=O)R'$, $-C_2(CR'R")_qO$ R', $-(CR'R")_qNR'R"$, -OC(=O)NR'R" and –NR'C(=O)OR' where R' and R" are individually hydrogen, lower alkyl, an aromatic group-containing species or a substituted aromatic group-containing species, and q is an integer from 1 to 6.

39. The pharmaceutical composition of Claim 38, wherein Y, Y', Y" and Y"' all are carbon bonded to a substituent species.

40. The pharmaceutical composition of Claim 38, wherein one or two of Y, Y', Y" and Y"' are nitrogen and the remaining are carbon bonded to a substituent species.

41. The pharmaceutical composition of Claim 38, wherein E', E" and E"' all are carbon bonded to substituent species.

42. The pharmaceutical composition of Claim 38, wherein one or two of E', E" and E"' are nitrogen and the remaining are carbon bonded to substituent species.

43. A method of treating central nervous system disorders comprising of administering to a subject in need thereof a therapeutically effective amount of a compound of the formula:



wherein Q is $(CH_2)_u$, Q^i is $(CH_2)_v$, Q^{ii} is $(CH_2)_w$, Q^{iii} is $(CH_2)_x$, and Q^{iv} is $(CH_2)_y$ where u, v, w and x are individually 0, 1, 2, 3 or 4 and y is 1 or 2; Z is a non-hydrogen substituent species characterized as having a sigma m value between -0.3 and about 0.75; j is from 0 to 10; R is hydrogen or lower alkyl; and Cy is



where each of X, X' and X" are individually nitrogen, nitrogen bonded to oxygen or carbon bonded to a substituent species characterized as having a sigma m value between about –0.3 and about 0.75; A is O or C=O; D is a non-hydrogen substituent species characterized as having a sigma m value between about –0.3 and about 0.75; k is 0, 1 or 2; and Cx is selected from a group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, non-aromatic heterocyclyl, substituted non-

aromatic heterocyclyl, non-aromatic heterocyclylalkyl and substituted non-aromatic heterocyclylalkyl.

44. The method according to Claim 43, wherein X" is nitrogen.

45. The method according to Claim 43, wherein X' and X" are nitrogen.

46. The method according to Claim 43, wherein j is 0, 1 or 2.

47. The method according to Claim 43, wherein the values of u, v, w, x and y are selected to provide a 7-, 8- or 9-membered diazabicyclic ring.

48. The method according to Claim 43, wherein Cx is selected from the group consisting of:





wherein Y, Y', Y" and Y'" are individually nitrogen, nitrogen bonded to oxygen, or carbon bonded to hydrogen or a substituent species, G; E is oxygen, sulfur or nitrogen

bonded to hydrogen or a substituent species, G; E', E" and E"' are individually nitrogen or carbon bonded to hydrogen or a substituent species, G; m is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; and G is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, -F, -Cl, -Br, -I, -OR', -NR'R", $-CF_3$, -CN, $-N_3$, $-NO_2$, $-C_2R'$, -SR', -SOR', $-SO_2CH_3$, $-SO_2NR'R"$, -C(=O)NR'R", -NR'C(=O)R", $-NR'SO_2R"$, -C(=O)R', -C(=O)OR', $-(CH_2)_qOR'$, $-OC(=O)R'$, $-(CR'R")_qOCH_2C_2R'$, $-(CR'R")_qC(=O)R'$, $-O(CR'R")_qC(=O)R'$, $-C_2(CR'R")_qO\ R'$, $-(CR'R")_qNR'R"$, -OC(=O)NR'R" and –NR'C(=O)OR' where R' and R" are individually hydrogen, lower alkyl, an aromatic group-containing species or a substituted aromatic group-containing species, and q is an integer from 1 to 6.

49. The method according to Claim 43, wherein Y, Y', Y" and Y"' all are carbon bonded to a substituent species.

50. The method according to Claim 48, wherein one or two of Y, Y', Y" and Y"' are nitrogen and the remaining are carbon bonded to a substituent species.

51. The method according to Claim 48, wherein E', E" and E"' all are carbon bonded to substituent species.

52. The method according to Claim 48, wherein one or two of E', E" and E"' are nitrogen and the remaining are carbon bonded to substituent species.

53. The method according to Claim 48, wherein the compound is selected from the group consisting of (1S,4S)-2-(5-(3-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(4-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(4-fluorophenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(3-thienyl)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane and (1S,4S)-2-(5-benzoyl-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane.

54. A method of treating central nervous system disorders comprising of administering to a subject in need thereof a therapeutically effective amount of a compound of the formula:



wherein Q is $(CH_2)_u$, Q^i is $(CH_2)_v$, Q^{ii} is $(CH_2)_w$, Q^{iii} is $(CH_2)_x$, and Q^{iv} is $(CH_2)_y$ where u, v, w and x are individually 0, 1, 2, 3 or 4 and y is 1 or 2; Z is a non-hydrogen substituent species characterized as having a sigma m value between -0.3 and about 0.75; j is from 0 to 10; R is hydrogen or lower alkyl; and Cy is



where each of X, X' and X" are individually nitrogen, nitrogen bonded to oxygen or carbon bonded to a substituent species characterized as having a sigma m value between about –0.3 and about 0.75; A is a covalent bond; D is a non-hydrogen substituent species characterized as having a sigma m value between about –0.3 and about 0.75; k is 0, 1 or 2; and Cx is selected from a group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, non-aromatic heterocyclylalkyl and substituted non-aromatic heterocyclylalkyl, with the proviso that the diazabicyclic ring is not 2,5-diazabicyclo[2.2.1]heptane and/or Cx is not phenyl or substituted phenyl.

55. The method of Claim 54, wherein X" is nitrogen.

56. The method of Claim 54, wherein X' and X" are nitrogen.

57. The method of Claim 54, wherein j is 0, 1 or 2.

58. The method of Claim 54, wherein the values of u, v, w, x and y are selected to provide a 7-, 8- or 9-membered diazabicyclic ring.

59. The method of Claim 54, wherein Cx is selected from the group consisting of:



wherein Y, Y', Y" and Y"' are individually nitrogen, nitrogen bonded to oxygen, or carbon bonded to hydrogen or a substituent species, G; E is oxygen, sulfur or nitrogen bonded to hydrogen or a substituent species, G; E', E" and E"' are individually nitrogen or carbon bonded to hydrogen or a substituent species, G; m is 0, 1, 2, 3 or 4; p is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; and G is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, non-aromatic heterocyclyl, substituted non-aromatic heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, -F, -Cl, -Br, -I, -OR', -NR'R", $-CF_3$, -CN, $-N_3$, $-NO_2$, $-C_2R'$, -SR', -SOR', $-SO_2CH_3$, $-SO_2NR'R"$, -C(=O)NR'R", -NR'C(=O)R", $-NR'SO_2R"$, -C(=O)R', -C(=O)OR', $-(CH_2)_qOR'$, -OC(=O)R', $-(CR'R")_qOCH_2C_2R'$, $-(CR'R")_qC(=O)R'$,

$-O(CR'R")_qC(=O)R'$, $-C_2(CR'R")_qO\ R'$, $-(CR'R")_qNR'R"$, $-OC(=O)NR'R"$ and $-NR'C(=O)OR'$ where R' and R" are individually hydrogen, lower alkyl, an aromatic group-containing species or a substituted aromatic group-containing species, and q is an integer from 1 to 6.

60. The method of Claim 59, wherein Y, Y', Y" and Y"' all are carbon bonded to a substituent species.

61. The method of Claim 59, wherein one or two of Y, Y', Y" and Y"' are nitrogen and the remaining are carbon bonded to a substituent species.

62. The method of Claim 59, wherein E', E" and E"' all are carbon bonded to substituent species.

63. The method of Claim 59, wherein one or two of E', E" and E"' are nitrogen and the remaining are carbon bonded to substituent species.